Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Filbert who wrote (1129)	8/9/1998 4:55:00 PM
From: yosi s	Respond to of 1491

to all that are comcern about manufactoring of pharmaceuticals. There are very few pharmaceutical companies that manufactor "bulk Product" most contract it out. and only do the last part of bottling etc. the manufactoring is not what makes a pharmaceutical company. Also the product it self HU211 is not very hard to do. Potential problem are in complex proteins etc. And PARS has had no problem in getting their produt through number of studies, both in animal and humans, and there was no issu with product being not pure etc.... The big expense is in Phase III human trials. It requires a lot of patients. in mutltiple centers. It was done by pars, and BOL with Lotemax and Alrex . Same process but HU211 got a huge market.